Skip to content

Inspiratory muscle training prior to peripheral muscle training in patients adolescents with Cystic Fibrosis.

Inspiratory muscle training prior to peripheral muscle training in patients adolescents with Cystic Fibrosis. - IMT in patients with Cystic Fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38371
Enrollment
60
Registered
2009-07-28
Start date
2010-03-12
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cystic fibrosis

Interventions

Included participants subsequently undergo: - 6 weeks of standardised (sham) IMT with an inspiratory threshold-loading device (Threshold IMT, PT Medical, Leek, The Netherlands). Progression of inten
5 BX). Frequency is 5 days a week, 11 minutes a day. Patients are instructed at follow-up points and controlled by e-mail and telephone by one of the physiotherapists from the WKZ (H.J. Hulzebos).

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
12 Years to 17 Years

Inclusion criteria

Inclusion criteria: •Ambulant patients with CF •Age: range from 12 to 18 years of age

Exclusion criteria

Exclusion criteria: - Acute gastro-intestinal or pulmonary exacerbation (extra oral or intravenous antibiotics for the past four weeks) at inclusion. - Oxygen saturation (SpO2)

Design outcomes

Primary

MeasureTime frame
The peak work rate in watts (Wpeak) achieved during the aerobic maximal exercise test (CPET). The main study parameter of the alternative protocol is the * time recovery of phosphocreatine (1/2 time PCr recovery) after maximal exercise.

Secondary

MeasureTime frame
- work of breathing in rest and during exercise - exercise capacity (except Wpeak) - disease specific and generic Health Related Quality of Life - habitual daily activity - respiratory muscle function - peripheral muscle function - rate of perceived exertion - patient specific goals - co morbidity - spirometry - anthropometry - use of medication and other care - compliance to interventions - feasibility of interventions and measurements - type of CF gene mutation

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)